Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lenti-MELA-12
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
Lenti-MELA-12 is an investigational lentiviral vector-based therapeutic cancer vaccine being developed by Theravectys for the treatment of melanoma. Utilizing Theravectys' proprietary lentiviral vector platform, which was developed in collaboration with the Institut Pasteur, the vaccine is designed to target and transduce dendritic cells in vivo. This transduction enables the endogenous presentation of melanoma-associated antigens, triggering a robust and long-lasting cellular immune response, particularly mediated by cytotoxic CD8+ T cells, to eliminate tumor cells and prevent recurrence. The candidate is currently in the discovery stage of development.
Beyond the preview
Go deeper on Lenti-MELA-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lenti-MELA-12.